Eli Lilly and Co (LTS:0Q1G) EBIT: CHF26,879 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0Q1G Eli Lilly and Co LTS:0Q1G
87 GF Score
Price CHF1,020.00
GF Value CHF882.28
Valuation Modestly Overvalued
! 2 Warning Signs
View Full Analysis

What is Eli Lilly and Co EBIT?

Eli Lilly and Co LTS:0Q1G 87 EBIT is CHF26,879 Mil as of Jun. 2026. GuruFocus rates LTS:0Q1G with a GF Score™ of 87/100 and a GF Value™ of CHF882.28 (Modestly Overvalued). The stock has 2 warning signs investors should review.

Eli Lilly and Co's earnings before interest and taxes (EBIT) for the three months ended in Jun. 2026 was CHF7,309 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Jun. 2026 was CHF26,879 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Eli Lilly and Co's annualized ROC % for the quarter that ended in Jun. 2026 was 32.14%. Eli Lilly and Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 88.96%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Eli Lilly and Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Jun. 2026 was 3.03%.


Eli Lilly and Co  (LTS:0Q1G) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Eli Lilly and Co's annualized ROC % for the quarter that ended in Jun. 2026 is calculated as:

ROC % (Q: Jun. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2026 ) + Invested Capital (Q: Jun. 2026 ))/ count )
=39383.409475758 * ( 1 - 23.272% )/( (85389.24075 + 102622.81965)/ 2 )
=30218.102422559/94006.0302
=32.14 %

where

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=93674.6448 - 4041.05295 - ( 4244.3511 - max(0, 29437.2507 - 44062.66425+4244.3511))
=85389.24075

Invested Capital(Q: Jun. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=114772.58195 - 4930.2448 - ( 7219.5175 - max(0, 38510.27765 - 52167.6688+7219.5175))
=102622.81965

Note: The Operating Income data used here is four times the quarterly (Jun. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Eli Lilly and Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2026  Q: Jun. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=29234.838839394/( ( (21326.217 + max(11387.10705, 0)) + (23623.5519 + max(9388.59935, 0)) )/ 2 )
=29234.838839394/( ( 32713.32405 + 33012.15125 )/ 2 )
=29234.838839394/32862.73765
=88.96 %

where Working Capital is:

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(14808.62295 + 11674.77795 + 11126.75685) - (4041.05295 + 0 + 22181.99775)
=11387.10705

Working Capital(Q: Jun. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(16199.95195 + 13546.07345 + 12465.9691) - (4930.2448 + 0 + 27893.15035)
=9388.59935

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Eli Lilly and Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Jun. 2026 )
=26879.291657896/885775.060
=3.03 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Eli Lilly and Co EBIT Related Terms


Eli Lilly and Co EBIT Historical Data

* Premium members only.

The historical data trend for Eli Lilly and Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eli Lilly and Co EBIT Chart

Eli Lilly and Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 5,938.43 6,817.25 6,326.96 11,854.67 21,369.24

Eli Lilly and Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5,603.72 5,931.22 6,703.88 6,935.48 7,308.71

LTS:0Q1G vs JNJ, ABBV, MRK: EBIT Comparison

For the Drug Manufacturers - General subindustry, Eli Lilly and Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eli Lilly and Co EV-to-EBIT vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Eli Lilly and Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Eli Lilly and Co's EV-to-EBIT falls into.


LTS:0Q1G
87GF Score
Eli Lilly and Co LTS:0Q1G
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eli Lilly and Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF26,879 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of CHF26,879 Mil mean?
Eli Lilly and Co (LTS:0Q1G) has a EBIT of CHF26,879 Mil as of Jun. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eli Lilly and Co.
Is Eli Lilly and Co's EBIT too high?
Eli Lilly and Co's current EBIT is CHF26,879 Mil. Overall, Eli Lilly and Co has a GF Score™ of 87/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Eli Lilly and Co's EBIT compare to JNJ and ABBV?
Eli Lilly and Co's EBIT of CHF26,879 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Drug Manufacturers company?
A good EBIT depends on the Drug Manufacturers industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Eli Lilly and Co. Eli Lilly and Co's current EBIT is CHF26,879 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eli Lilly and Co stock overvalued right now?
Based on GuruFocus' analysis, Eli Lilly and Co (LTS:0Q1G) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF882.28, compared to a current price of CHF1,020.00 — trading 15.6% above its estimated fair value. The current EBIT is CHF26,879 Mil. Eli Lilly and Co's overall GF Score™ is 87/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Eli Lilly and Co (LTS:0Q1G), the current EBIT is CHF26,879 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Eli Lilly and Co (LTS:0Q1G) Overvalued in 2026?

Based on GuruFocus' analysis, Eli Lilly and Co stock appears to be overvalued. The current stock price of CHF1,020.00 is trading 15.6% above its estimated GF Value™ of CHF882.28. GuruFocus considers Eli Lilly and Co to be Modestly Overvalued.

Key valuation signals for LTS:0Q1G:

  • EBIT: CHF26,879 Mil
  • GF Value™: CHF882.28 vs. price of CHF1,020.00 (15.6% above fair value)
  • GF Score™: 87/100 with 2 warning signs

No single metric tells the full story. See the LTS:0Q1G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Eli Lilly and Co Business Description

Address Lilly Corporate Center, Indianapolis, IN, USA, 46285
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
87GF Score

Get the complete analysis for LTS:0Q1G

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

CHF1,020.00
Price
CHF882.28
GF Value